HighVista Strategies’s Structure Therapeutics GPCR Stock Holding History

HighVista Strategies’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.02M	Buy	130,784 +6,875	+6%	+$304K	1.6%	13
2026 Q1	$5.97M	Sell	123,909 -69,092	-36%	-$4.73M	1.65%	9
2025 Q4	$13.4M	Sell	193,001 -43,235	-18%	-$1.77M	3.46%	2
2025 Q3	$6.61M	Buy	236,236 +149,615	+173%	+$2.98M	1.62%	15
2025 Q2	$1.8M	Buy	86,621 +69,060	+393%	+$1.52M	0.66%	51
2025 Q1	$304K	Hold	17,561	–	–	0.12%	139
2024 Q4	$476K	Sell	17,561 -14,157	-45%	-$502K	0.18%	123
2024 Q3	$1.39M	Sell	31,718 -3,410	-10%	-$132K	0.48%	88
2024 Q2	$1.38M	Sell	35,128 -2,316	-6%	-$95.1K	0.5%	74
2024 Q1	$1.6M	Sell	37,444 -37,388	-50%	-$1.58M	0.57%	61
2023 Q4	$3.05M	Hold	74,832	–	–	1.11%	27
2023 Q3	$3.77M	Buy	+74,832	New	+$2.41M	1.75%	11

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HighVista Strategies's GPCR Position: Q2 2026 in Review

HighVista Strategies increased its Structure Therapeutics (GPCR) stake by 5.5% in Q2 2026, buying an estimated $304K and bringing the position to 130,784 shares worth $7.02M. The position accounts for 1.6% of the portfolio, ranked #13.

HighVista Strategies first reported a position in GPCR in Q3 2023 and has held it in 12 quarters since. The position peaked at $13.4M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

HighVista Strategies held 130,784 shares of Structure Therapeutics worth $7.02M as of Q2 2026.
HighVista Strategies bought 6,875 Structure Therapeutics shares in Q2 2026, an estimated $304K.
Structure Therapeutics made up 1.6% of HighVista Strategies's portfolio in Q2 2026, its #13 holding.
HighVista Strategies first reported a position in Structure Therapeutics in Q3 2023 and has held it in 12 quarters since.
HighVista Strategies's Structure Therapeutics position peaked at $13.4M in Q4 2025.
191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.